Highlights

  • On 5 August 2026, Clarity released an update on its SECuRE trial, a Phase I/IIa study testing 67Cu-SAR-bisPSMA, its copper-67 labelled therapeutic candidate, in men with metastatic castration-resistant prostate cancer.
  • As of a Google Finance snapshot at 2:29pm AEST on 10 August 2026, Clarity shares traded around AUD 2.92, valuing the company at approximately AUD 1.09 billion.
  • Investors will be watching for further SECuRE readouts, progress in the CLARIFY Phase III diagnostic trial, and news on dose selection for a potential pivotal therapeutic trial of 67Cu-SAR-bisPSMA.
  • The other side of the ledger is standard clinical-stage biotech risk, and it is real.

Clarity Pharmaceuticals shares were among the standout performers on the ASX on 10 August 2026, rising 4.46% according to a TradingView top-gainers screener, as the clinical-stage radiopharmaceutical developer rode ongoing sentiment from a trial update released five days earlier. The Sydney-headquartered company, which is building a pipeline of copper-based diagnostic and therapeutic products for cancer, told the market on 5 August that its SECuRE trial of 67Cu-SAR-bisPSMA in prostate cancer had produced two additional complete responses at its highest tested dose. For a company with no approved products and no Revenue , share-price moves of this size are common on trial news, and this latest gain adds to what has been a volatile year for the stock.

Recent Developments

On 5 August 2026, Clarity released an update on its SECuRE trial, a Phase I/IIa study testing 67Cu-SAR-bisPSMA, its copper-67 labelled therapeutic candidate, in men with metastatic castration-resistant prostate cancer. The update covered 19 participants - three from dose escalation and 16 from cohort expansion - with a data cut-off of 20 July 2026. This was a heavily pre-treated group: 79% had already had five or more prior anti-cancer regimens and 63% had bone metastases.

At the 8 GBq dose level, 74% of participants achieved a PSA25 response (a fall of 25% or more in prostate-specific antigen), 63% achieved PSA50 and 26% achieved PSA90. Among 16 evaluable participants, 81% achieved disease control on radiographic assessment, and five achieved a complete response or undetectable disease - 31% of those evaluable at that dose. Across the whole program to date, seven participants have now achieved a complete response or undetectable disease. Executive Chairperson Dr Alan Taylor said "almost a third of all evaluable patients treated at this dose level have achieved a complete response and/or undetectable disease." Adverse events were mostly Grade 1-2, gastrointestinal or haematological, with no Grade 4 events reported.

Why It Matters

Prostate cancer remains one of the largest addressable markets in oncology, and radioligand therapy has become one of the more closely watched sub-sectors since Novartis's Pluvicto secured approval and built a multibillion-dollar Franchise . Clarity is positioning SAR-bisPSMA as a more targeted alternative, so any sign that its therapeutic candidate can produce durable complete responses in heavily pre-treated patients is the kind of data point investors in this space watch closely. Small, single-arm early-phase numbers like these do not prove efficacy on their own, but they inform dose selection for the pivotal trials the company will eventually need to run, and they feed a narrative that has kept Clarity among the more actively traded biotech names on the ASX.

Bulls point to a well-funded Balance Sheet by clinical-biotech standards, a pipeline spread across three distinct targets rather than a single-asset bet, and trial data that keeps showing complete responses in a hard-to-treat, heavily pre-treated patient population. The company already has Manufacturing infrastructure being built out ahead of any approval, two Rare Pediatric Disease Designations attached to SARTATE that could carry a Priority Review Voucher worth roughly US$100 million if converted, and a board recently strengthened with outside pharmaceutical Leadership experience. For investors who buy the theranostic thesis - using the same molecule to image and then treat a tumour - Clarity is one of the more advanced ASX-listed names pursuing it.

Investment decisions remain tied to the milestones, funding needs and risks outlined above.

The Assets described above remain central to the company's valuation and strategic case.

Company Overview

Clarity Pharmaceuticals develops what it calls Targeted Copper Theranostics, pairing its proprietary SAR chelator technology with copper isotopes - copper-64 for diagnostic imaging and copper-67 for therapy - so the same targeting molecule can, in principle, both find and treat cancer. The lead program, SAR-bisPSMA, targets prostate-specific membrane antigen via trials including SECuRE (therapeutic, USA), CLARIFY (Phase III diagnostic, 383 patients across the US and Australia), and the completed COBRA and PROPELLER diagnostic studies. A second program, SAR-Bombesin, targets the gastrin-releasing peptide receptor in prostate and other cancers, including PSMA-negative patients, via trials such as SABRE, COMBAT and the completed C-BOBCAT breast cancer study. A third, SARTATE, targets somatostatin receptor 2 for neuroendocrine tumours and paediatric neuroblastoma, and carries two Rare Pediatric Disease Designations from the FDA. The company reached its 100th employee in June 2026, up around 45% for the financial year, and in July 2026 appointed Allison Rossiter, a former Novartis and Roche executive, as an independent non-executive director.

Financial Snapshot

As of a Google Finance snapshot at 2:29pm AEST on 10 August 2026, Clarity shares traded around AUD 2.92, valuing the company at approximately AUD 1.09 billion. The 52-week range has been wide, roughly AUD 1.80 to AUD 5.87, underlining how sharply sentiment can swing on trial newsflow for a pre-revenue biotech. In its quarterly activity report for the three months to 30 June 2026, Clarity reported cash of AUD 178.3 million and net cash used in Operating Activities of AUD 19.3 million for the quarter, implying an estimated runway of roughly nine quarters at that Burn Rate . The company also banked a AUD 9.8 million R& Amp ;D tax incentive refund in May 2026, and in April 2026 signed a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA, targeting 50,000 doses a year from Minnesota, scaling toward 600,000 doses annually once a planned Pennsylvania site opens in 2028.

Cash Flow remains central to funding capacity and the company's ability to execute its next milestones.

Earnings remain an important measure of whether current momentum is supported by underlying Business performance.

Market Capitalisation remains a useful reference point for how the market is valuing the story described above.

What to Watch

Investors will be watching for further SECuRE readouts, progress in the CLARIFY Phase III diagnostic trial, and news on dose selection for a potential pivotal therapeutic trial of 67Cu-SAR-bisPSMA. On SARTATE, the company has flagged plans for a registrational Phase III trial following discussions with the FDA. The next scheduled disclosure is the quarterly activity report due in late October 2026, which should update the cash position and burn rate.

Risks

The other side of the ledger is standard clinical-stage biotech risk, and it is real. The SECuRE data behind this rally comes from just 19 participants, with only 16 evaluable for radiographic response - encouraging, but far too small to draw firm conclusions about eventual approval or commercial success. Clarity remains pre-revenue and continues to burn cash, and while nine quarters of runway is comfortable today, further capital raisings are likely before any product reaches market, which can dilute shareholders. The radioligand field is increasingly competitive, manufacturing scale-up carries execution risk, and regulatory approval is never guaranteed. The stock's 52-week range spanning more than three-fold is a reminder that gains built on early-stage readouts can reverse just as quickly on a disappointing one.

What Could Move SECuRE Toward A Larger Clinical Opportunity

Monday's gain fits a pattern that has defined Clarity Pharmaceuticals' year: incremental but encouraging trial data feeding a share price that moves in large steps, in either direction, around each announcement. The fundamentals - a well-capitalised balance sheet, a broadening pipeline, and manufacturing already being scaled ahead of approval - give the bull case real substance. But the company remains years from its first product approval and revenue, and the sample sizes behind headlines like this week's are still small. Shareholders should treat this as one data point in a long clinical development story rather than a destination.